Search Bar & Filters
Found 18 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the use of sodium zirconium cyclosilicate SZC to help optimize renin-angiotensin aldosterone system inhibitor RAASi therapies in elderly patients aged 70 and older who have heart failure and chronic kidney disease. Many patients with these conditions do not receive recommended RAASi doses because of elevated potassium levels, which can be dangerous. This study aims to see if adding SZC allows safer and more effective use of RAASi medications by managing potassium levels. This is a randomized, open-label clinical trial where eligible participants who have been hospitalized for heart failure worsening and have mild or at-risk hyperkalemia will be assigned to one of two groups. One group receives SZC along with standard RAASi treatment, while the other receives RAASi treatment alone without potassium binders. The treatment period lasts three months, during which RAASi doses are adjusted following European Society of Cardiology guidelines. Participants will be monitored from screening through three months of treatment to measure how many can increase their RAASi doses by at least 25%. Evaluations include clinical assessments, potassium level monitoring, and adherence to therapy. The study will also track secondary outcomes related to higher dose increases. Safety and treatment effects will be observed throughout the trial, which is expected to provide important insights for managing these conditions in elderly patients.
Actively Recruiting
Researchers are conducting a prospective, multicenter observational study to create a registry for patients diagnosed with unresectable locally advanced or metastatic breast cancer, either after recurrence or as a first diagnosis since January 2016. This study aims to understand the distribution of different breast cancer subtypes and patient characteristics over an 8-year period. No specific treatment is assigned by the study, and clinical decisions are made independently by the treating physicians. Participants are grouped based on breast cancer subtypes characterized by receptors such as Estrogen receptor ER, Progesterone receptor PgR, HER2, and Ki-67 expression levels. The study does not intervene in treatment instead, it observes patients receiving standard care as decided by their doctors. Patients may include males and females, and there is no age upper limit. Data collection includes patient and tumor characteristics, biomarker presence in tumor and blood samples, and the impact of surgery timing on patients initially diagnosed with metastatic disease. During the study, participants medical records and disease management data are accessed for analysis. Researchers collect information over 8 years, including subtype distribution, heredofamilial risk, gender differences in disease progression, and biomarker frequency. Patients can withdraw consent at any time, and the treating clinician is encouraged to follow patients until death or study completion. The studys primary outcome is the number of patients with various breast cancer subtypes, with several secondary outcomes related to disease characteristics and treatment timing.
Actively Recruiting
Researchers are evaluating the combination of calderasib and pembrolizumab as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer NSCLC that has a specific KRAS G12C mutation and a PD-L1 tumor proportion score of 50% or higher. The study aims to determine if this combination improves progression-free survival compared to pembrolizumab with placebo. This is a phase 3 randomized, double-blind trial sponsored by Merck Sharp & Dohme LLC. Participants will receive pembrolizumab 200 mg through intravenous infusion on the first day of each 21-day cycle, continuing for up to 35 cycles. In addition, they will take either calderasib or placebo tablets daily until they meet discontinuation criteria. The study includes two groups one receiving calderasib plus pembrolizumab and the other receiving placebo plus pembrolizumab. No new participants will be offered a second course of pembrolizumab. Throughout the study, participants will undergo various assessments including tumor evaluations by central review to measure progression-free survival, overall survival, and response rates. Quality of life and physical functioning will be monitored using standardized questionnaires up to 24 months. Safety will be tracked by recording adverse events and treatment discontinuations for up to approximately 80 months. The total study duration extends up to 7 years, with ongoing monitoring throughout.
Actively Recruiting
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
Actively Recruiting
Researchers are conducting a phase 1, multicenter, nonrandomized, open-label study to evaluate YL201 in patients with advanced solid tumors that have not responded to current treatments or lack standard therapy options. The study includes two parts Part 1 focuses on finding the maximum tolerated dose and recommended dose levels through dose escalation, while Part 2 enrolls patients with selected tumor types to further assess safety and efficacy of YL201. Participants will receive YL201 as an intravenous infusion once every three weeks in cycles. Some patients may receive YL201 alone at different dosages or in combination with atezolizumab during each 21-day cycle. Part 1 involves dose escalation cohorts to determine appropriate dosing, followed by Part 2 dose expansion cohorts to better define safety and evaluate treatment responses. Throughout the study, participants undergo tumor evaluations using RECIST criteria, laboratory tests, and safety monitoring to track adverse events, dose-limiting toxicities, and pharmacokinetics. For prostate cancer patients, prostate-specific antigen response and progression-free survival will be measured. The study lasts approximately 36 months, with ongoing assessments of tumor response, survival, and laboratory abnormalities conducted at regular intervals.
Actively Recruiting
Researchers are evaluating how well the 20-valent pneumococcal conjugate vaccine 20vPnC works against pneumonia caused by seven new types of the Streptococcus pneumoniae bacteria. This study focuses on adults aged 65 years and older who are hospitalized with pneumonia confirmed by chest imaging. The study aims to compare the presence of pneumonia caused by these specific bacteria types in people vaccinated with 20vPnC versus those with pneumonia caused by other bacteria or strains. This observational study involves adults 65 years and older hospitalized with radiologically-confirmed community-acquired pneumonia RADCAP. Participants will provide a urine sample for testing pneumococcal bacteria using BinaxNOW and specific urinary antigen detection assays UAD-1 and UAD-2. Cases are identified by detection of the seven additional bacteria types in 20vPnC beyond the previous 13-valent vaccine, while controls include other pneumonia cases without these serotypes. No treatment is given as part of the study. Participants will be involved for about 1 to 2 days for urine sample collection and providing medical history. Researchers will collect detailed information on illness and hospital stay up to 30 days through medical record review. The main outcome measured is the effectiveness of 20vPnC against pneumonia caused by the seven additional bacterial types over approximately 55 months. Other clinical features and pneumonia types will also be reviewed during this period.
Actively Recruiting
This observational, prospective study focuses on patients with post-percutaneous coronary intervention PCI angina who are referred for invasive coronary angiography ICA. It aims to identify the causes and origins of post-PCI angina using an advanced invasive diagnosis AID strategy combined with angiography derived physiology ADP. The study includes patients with a history of PCI who present angina or documented myocardial ischemia, investigating both obstructive and non-obstructive causes of ischemia. Participants undergo ICA with the structured AID strategy, starting with coronary angiography to evaluate severe-grade stenosis. Intermediate-grade stenosis is further assessed using fractional flow reserve FFR and non-hyperaemic pressure ratios NHPR. Patients with non-obstructive coronary artery disease or normal arteries undergo tests for microcirculatory and vasomotor disorders. ADP is applied using specialized software to analyze coronary angiograms from both the current and previous procedures. Treatment decisions are made by clinicians based on these assessments. Patients complete the Seattle Angina Questionnaire SAQ at baseline and at 1, 6, and 12 months after the procedure to evaluate angina symptoms. The main outcome is the proportion of patients in whom the origins of obstructive disease and causes of post-PCI angina are identified. The study also measures angina symptom improvement at 6 months. Follow-up includes clinical evaluations and symptom questionnaires to monitor outcomes over one year.
Actively Recruiting
Researchers are studying breast cancer patients who have a positive sentinel lymph node after receiving neoadjuvant systemic treatment. The trial evaluates whether axillary radiotherapy ART reduces the risk of lymphedema compared to axillary lymph node dissection ALND in these patients. The study also examines recurrence and overall survival rates, as well as quality of life. This is a prospective, randomized, open-label, parallel group, multicenter study involving approximately 820 patients over 5 years. Participants are divided into two groups one receives axillary radiotherapy without lymphadenectomy, including radiation to levels I and II axilla, level III, supraclavicular area, and possibly the internal mammary chain the other group undergoes axillary lymph node dissection plus radiotherapy to level III, supraclavicular area, and possibly the internal mammary chain. Patients are stratified by neoadjuvant treatment type chemotherapy or hormone therapy. A pilot phase with the first 200 patients has been completed, and interim analysis will be performed. During the study, participants undergo evaluations including imaging by ultrasound or MRI to assess axillary response after neoadjuvant therapy. Researchers will track disease-free survival up to 5 years, overall survival up to 5 years, and incidence of lymphedema up to 3 years after surgery. Quality of life and safety outcomes will also be monitored. The study aims to provide data on whether avoiding lymphadenectomy is a viable option for patients responding well to neoadjuvant treatment.
Actively Recruiting
Researchers are evaluating the effects of a low-intensity muscle strengthening program combined with Blood Flow Restriction Training BFRT on upper limb strength, muscle fatigue, coordination, dexterity, functionality, and quality of life in people with multiple sclerosis MS. This randomized controlled trial compares this approach to a conventional high-intensity strengthening program. The study aims to fill the gap in research about BFRTs impact on forearm and hand muscles in individuals with MS and to assess adherence and satisfaction with the intervention. Participants will be randomly assigned to one of two groups a control group performing a conventional high-intensity strengthening program using dumbbells at 70% of one repetition maximum 1RM with 4 sets of 8-12 repetitions, and an experimental group performing a low-intensity strengthening program at 20% 1RM combined with the BFRT system. The BFRT will be applied via an external pneumatic tourniquet at 60% of the total restriction pressure TRP during exercises involving palmar flexion, dorsal flexion, ulnar deviation, radial deviation, pronation, supination, and elbow flexion and extension. Each session includes rest periods based on fatigue. Participants will undergo assessments before, immediately after, and during follow-up up to 8 weeks. Evaluations include isometric hand strength, coordination tests, functional status of the upper limb, quality of life questionnaires, and satisfaction surveys. Researchers will monitor safety, feasibility, and adherence throughout the study, which is scheduled to start in March 2025 and run until December 2026. The total number of participants planned is 21, accounting for possible dropouts.
Actively Recruiting
Researchers are studying the use of ribociclib, a CDK46 inhibitor, in women with early hormone receptor-positive HR and HER2-negative breast cancer who are at intermediate risk of cancer recurrence. The study aims to see if patients can avoid chemotherapy, which has significant side effects, by using ribociclib along with hormone therapy after surgery. This phase III trial builds on the NATALEE study, which showed that ribociclib added to hormone therapy improved survival free of invasive disease in similar patients. Participants will be randomly assigned to one of two groups one receiving ribociclib plus endocrine hormone therapy, and the other receiving chemotherapy followed by ribociclib and endocrine therapy. Ribociclib treatment lasts for three years, and chemotherapy is given before starting ribociclib and hormone treatment. The trial aims to compare the outcomes of chemotherapy de-escalation versus standard treatment in this patient group. During the study, participants will attend scheduled visits for treatment and monitoring, including laboratory tests, heart monitoring with ECG, and questionnaires about their quality of life. Researchers will track invasive breast cancer-free survival and other outcomes such as overall survival and treatment side effects for up to 12 years. Safety and quality of life assessments will continue during and after treatment to evaluate the long-term effects and benefits of the treatment approaches.
1-10 of 18
1